Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

Abstract Background In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration–approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and 43% in metastatic basal cell carcinoma (mBCC) and l...

Full description

Bibliographic Details
Main Authors: Aleksandar Sekulic, Michael R. Migden, Nicole Basset-Seguin, Claus Garbe, Anja Gesierich, Christopher D. Lao, Chris Miller, Laurent Mortier, Dedee F. Murrell, Omid Hamid, Jorge F. Quevedo, Jeannie Hou, Edward McKenna, Natalie Dimier, Sarah Williams, Dirk Schadendorf, Axel Hauschild, for the ERIVANCE BCC Investigators
Format: Article
Language:English
Published: BioMed Central 2017-05-01
Series:BMC Cancer
Subjects:
Basal cell carcinoma (BCC)
Vismodegib
Long-term
Safety
Efficacy
Online Access:http://link.springer.com/article/10.1186/s12885-017-3286-5

Internet

http://link.springer.com/article/10.1186/s12885-017-3286-5

Similar Items